<DOC>
	<DOCNO>NCT03086291</DOCNO>
	<brief_summary>Simvastatin 5-10mg/kg bid 7 day 14 day treatment 21 day Cohort 1 : 7.5 mg/kg bid 7 day 14 day Cohort 2 : 10 mg/kg bid 7 day 14 day Cohort 3 : ( ) mg/kg bid 7 day 14 day ( determine base PK data cohort 1 2 ) Q 3 week</brief_summary>
	<brief_title>A Phase I Study High Dose Simvastatin Patients With Gastrointestinal Tract Cancer Who Failed Standard Chemotherapy</brief_title>
	<detailed_description>This Phase 1 , open-label , single center , dose escalation study evaluate safety , tolerability pharmacokinetics high dose simvastatin patient GI cancer . Three dose level evaluate . Simvastatin give escalate dose 7.5mg/kg bid , 10mg/kg bid ( ) mg/kg bid 7 day treatment 14 day ( Final dose determine base PK data cohort 1 2 ) . The treatment repeat every 3 week . The cohort size least 3 6 patient ( 'rolling six design ' ) employ improve rate accrual patient cohort close presume therapeutic dose reduce need late replacement patient become non-evaluable DLT assessment period , whilst compromise collection safety data . The total number patient depend upon number dose adjustment necessary . And intra-patient dose escalation allow .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1 . Be willing able provide write informed consent/assent trial . 2 . Be 20 year age day sign informed consent 3 . Have histologically cytologically confirm diagnosis colorectal cancer gastric cancer 4 . For colorectal cancer , patient progress 5FU capecitabine , irinotecan , oxaliplatin , bevacizumab cetuximab treatment ( cetuximab KRAS/NRAS wild type ) 5 . For gastric cancer , patient progress second line chemotherapy . 6 . Have performance status 0 1 ECOG Performance Scale . 7 . Have evaluable disease base RECIST v1.1 determine investigator . 8 . Be willing provide blood sample PK analysis . 9 . Ability swallow retain oral medication . 10 . Demonstrate adequate organ function 1 . Prior history statin within 12 month date study entry 2 . Patients massive ascites disseminate bone metastasis 3 . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . This exception include carcinomatous meningitis exclude regardless clinical stability . 4 . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer . 5 . Has active infection require systemic therapy . 6 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 7 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 8 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . 9 . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . 10 . Patients CPK &gt; ULN baseline</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>